Shares of Anavex Life Sciences Corp (NASDAQ:AVXL) saw unusually-high trading volume on Wednesday . Approximately 2,837,900 shares were traded during mid-day trading, an increase of 622% from the previous session’s volume of 393,254 shares.The stock last traded at $3.03 and had previously closed at $2.36.
AVXL has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Anavex Life Sciences has a consensus rating of “Buy” and a consensus target price of $9.20.
The company has a market cap of $159.53 million, a price-to-earnings ratio of -7.77 and a beta of 2.17. The company has a fifty day moving average price of $2.58 and a two-hundred day moving average price of $2.89.
Anavex Life Sciences Company Profile (NASDAQ:AVXL)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
See Also: How is the LIBOR rate calculated?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.